TGFB-enabled anti-B7H3 CAR T-cell therapy (Children's Hospital Los Angeles)

N/A

Report date: 2025/06/11 10:41:57

Base Information

Drug NameTGFB-enabled anti-B7H3 CAR T-cell therapy (Children's Hospital Los Angeles)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionCD276 antigen modulatorsTransforming growth factor beta receptors agonistsImmunostimulants +[4]

TargetsTransforming growth factor beta receptorsCD276 antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesChildren'S Hospital Los Angeles

China Registration ClassN/A

Develop Information

Active CompaniesChildren'S Hospital Los Angeles

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A